NCT03594747

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 360 (actual)
• Sponsor: BeiGene · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	Administered intravenously as described
DRUG	Paclitaxel	Administered intravenously as described
DRUG	Nab-paclitaxel	Administered intravenously as described
DRUG	Carboplatin	Administered intravenously as described

Timeline

• Start date: 2018-07-30
• Primary completion: 2020-09-30
• Completion: 2023-04-28
• First posted: 2018-07-20
• Last updated: 2024-10-26
• Results posted: 2023-10-17

Locations

43 sites across 1 country: China

Regulatory

• FDA-regulated drug study